Psychosis in Parkinson's and Alzheimer's Disease Market to Reach USD 6.5 Billion by 2034

Psychosis is a severe non-motor complication associated with Parkinson's disease (PD) and Alzheimer's disease (AD). It is characterized by visual hallucinations, delusions, agitation, and paranoia, which worsen disease progression and caregiver burden. Psychosis develops in up to 60% of Parkinson's patients and nearly 40% of Alzheimer's patients, making it a critical challenge in neurodegenerative care.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71923

Current treatment options are limited, as standard antipsychotics worsen motor and cognitive symptoms. The introduction of novel therapies, such as pimavanserin (Nuplazid) and investigational serotonergic agents, alongside digital health platforms and biomarker-driven psychiatry, is transforming the market outlook.

Market Overview
• Market Size (2024): USD 3.5 billion
• Forecast (2034): USD 6.5 billion
• CAGR (2025-2034): 6.3%

Growth is fueled by rising prevalence of neurodegenerative diseases, FDA/EMA approvals of safer antipsychotics, and integration of digital health monitoring tools.

Key Highlights:
• Pimavanserin remains the only FDA-approved drug specifically for PD psychosis.
• High unmet need in Alzheimer's-related psychosis due to safety issues with traditional drugs.
• AI-driven neuropsychiatric monitoring improving early intervention.
• Pipeline research exploring serotonergic, glutamatergic, and neurosteroid-based agents.

Segmentation Analysis
By Product Type:
• Pharmacological Therapies
o Pimavanserin (Nuplazid - FDA approved for PD psychosis)
o Clozapine, Quetiapine (used cautiously in PD/AD psychosis)
o SSRIs/SNRIs (adjunctive use in behavioral symptoms)
o Pipeline Agents (serotonergic modulators, glutamate-based therapies, neurosteroids)
• Non-Pharmacological Interventions
o Cognitive Behavioral Therapy (CBT) for hallucination coping
o Caregiver Training Programs
• Digital Health Solutions
o AI-Based Behavioral Monitoring
o Telepsychiatry for Elderly Patients
o Virtual Reality (VR) Calming Environments

By Platform:
• Small Molecules (pimavanserin, quetiapine)
• Biologics (emerging neuropsychiatric immunotherapies)
• Digital & Non-Drug Interventions

By Technology:
• AI-Powered Psychiatry Platforms
• Biomarker-Based Diagnostics (CSF, PET imaging for psychosis risk)
• Digital Therapeutics

By End Use:
• Hospitals & Neurology Clinics
• Memory Care Centers
• Home Care Settings
• Research Institutes

By Application:
• Parkinson's Disease Psychosis
• Alzheimer's Disease Psychosis
• Clinical Research

Segmentation Summary:
Pharmacological treatments dominate, but digital health tools, biomarkers, and novel serotonergic/glutamatergic drugs represent the fastest-growing categories.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71923

Regional Analysis
North America
• ~45% share in 2024.
• Strong adoption of pimavanserin and digital monitoring tools.
• FDA supporting neuropsychiatric drug pipelines.
Europe
• ~30% share.
• Germany, UK, and France leading integrated dementia and PD psychosis care.
• EMA pipeline reviews expanding therapy access.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.5%.
• Rising neurodegenerative burden in Japan, China, and India.
• Expanding memory clinics and telepsychiatry adoption.
Middle East & Africa
• Smaller market but rising with aging populations.
• Limited specialized dementia and Parkinson's care centers.
Latin America
• Brazil and Mexico driving demand.
• Growing use of generics and caregiver support platforms.
Regional Summary:
North America and Europe dominate today's market, while Asia-Pacific grows fastest with rising prevalence, healthcare expansion, and digital health adoption.

Market Dynamics
Key Growth Drivers:
• Rising prevalence of PD and AD globally.
• FDA/EMA approvals of safer psychiatric drugs like pimavanserin.
• Growing digital psychiatry platforms for elderly care.
• Increasing focus on caregiver support and burden reduction.

Key Challenges:
• Limited efficacy and high relapse rates with current drugs.
• Safety concerns of antipsychotics in elderly patients.
• High treatment costs and access limitations in low-income countries.
• Underdiagnosis of psychosis in early PD and AD.

Latest Trends:
• Expansion of serotonergic and glutamatergic drug pipelines.
• AI-based digital monitoring for hallucination tracking.
• Integration of telepsychiatry and VR-based therapies.
• Development of biomarker-driven psychiatry for early detection.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71923/psychosis-in-parkinson-s-and-alzheimer-s-disease-market

Competitor Analysis
Major Players in the Market:
• ACADIA Pharmaceuticals Inc. (Pimavanserin - Nuplazid)
• Eli Lilly and Company
• Johnson & Johnson (Janssen Pharmaceuticals)
• Novartis AG
• Pfizer Inc.
• Roche Holding AG (biomarker and neurodegenerative research)
• Biogen Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Lundbeck A/S
• MindMaze (digital neurotherapeutics)

Competitive Summary:
ACADIA dominates with pimavanserin, while Eli Lilly, Roche, and Biogen explore neuropsychiatric drug pipelines. Novartis, Pfizer, and J&J maintain strong CNS portfolios. MindMaze and digital firms pioneer VR and AI psychiatry solutions. Competition is focused on drug innovation, biomarker integration, and digital health expansion.

Conclusion
The Psychosis in Parkinson's and Alzheimer's Disease Market, valued at USD 3.5 billion in 2024, is projected to reach USD 6.5 billion by 2034, growing at a CAGR of 6.3%. Expanding drug pipelines, digital psychiatry, and biomarker-driven approaches will continue to reshape the market.

Key Takeaways:
• Pimavanserin leads PD psychosis treatment, but AD psychosis remains underserved.
• North America and Europe dominate, while Asia-Pacific grows fastest.
• Digital health and AI platforms will improve diagnosis and monitoring.
• Future growth will come from integrated multimodal care models combining pharmacology, digital tools, and caregiver support.

The next decade will move psychosis care in PD and AD from limited symptomatic management toward precision psychiatry and digital integration, creating opportunities for pharma, biotech, and digital innovators.

This report is also available in the following languages : Japanese (パーキンソン病およびアルツハイマー病市場における精神病), Korean (파킨슨병 및 알츠하이머병 시장의 정신병), Chinese (帕金森病和阿尔茨海默病中的精神病市场), French (Marché de la psychose dans la maladie de Parkinson et d'Alzheimer), German (Psychosen im Parkinson- und Alzheimer-Markt), and Italian (Psicosi nel mercato del morbo di Parkinson e di Alzheimer), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71923/psychosis-in-parkinson-s-and-alzheimer-s-disease-market#request-a-sample

Our More Reports:

Voluntary Carbon Credit Market
https://exactitudeconsultancy.com/reports/72383/voluntary-carbon-credit-market

Companion Animal Health Market
https://exactitudeconsultancy.com/reports/72382/companion-animal-health-market

Cannabi Oil Market
https://exactitudeconsultancy.com/reports/72381/oil-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.